Loading...
•
Dec 31, 2024
Vir Q4 2024 Earnings Report
Vir Biotechnology reported its fourth quarter and full year 2024 financial results, highlighting progress in its chronic hepatitis delta and solid tumor programs.
Key Takeaways
Vir Biotechnology reported a net loss of $(104.6) million for Q4 2024, an improvement from $(116.0) million in Q4 2023. Total revenues for the quarter were $12.4 million, down from $16.8 million in the prior year. The company ended the year with $1.10 billion in cash, cash equivalents, and investments, providing a cash runway into mid-2027.
Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta is on track to begin in the first half of 2025.
Tobevibart and elebsiran in chronic hepatitis delta received U.S. FDA Breakthrough and Fast Track designations, and EMA PRIME and Orphan Drug designations.
Dual-masked T-cell engagers VIR-5818 and VIR-5500 showed compelling early clinical response signals and promising safety profiles in solid tumors.
The company plans to initiate a Phase 1 study of VIR-5525, its dual-masked EGFR-targeting T-cell engager, in the first half of 2025.
Revenue by Segment
Forward Guidance
Based on current operating plans, Vir Biotechnology expects its cash, cash equivalents, and investments to fund its operations into mid-2027.
Positive Outlook
- Sufficient cash runway into mid-2027.
- Initiation of Phase 3 registrational program in chronic hepatitis delta in H1 2025.
- Further clinical progression of dual-masked T-cell engagers in solid tumors.
- Planned initiation of Phase 1 study for VIR-5525 in H1 2025.
- Focused prioritization and disciplined capital deployment.
Challenges Ahead
- Future advancement in CHB contingent on securing a worldwide development and commercialization partner outside of China Territory.
- Potential for unexpected safety or efficacy data in clinical studies.
- Risks of unexpected costs, delays, or other hurdles.
- Difficulties in collaborating with other companies.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...